These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855 [TBL] [Abstract][Full Text] [Related]
44. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features. Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865 [TBL] [Abstract][Full Text] [Related]
45. Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. Myhre PL; Claggett B; Yu B; Skali H; Solomon SD; Røsjø H; Omland T; Wiggins KL; Psaty BM; Floyd JS; Selvin E; Ballantyne CM; Shah AM JAMA Cardiol; 2022 Jun; 7(6):623-631. PubMed ID: 35476049 [TBL] [Abstract][Full Text] [Related]
46. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791 [TBL] [Abstract][Full Text] [Related]
48. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis. Barker N; Judge DP Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601 [TBL] [Abstract][Full Text] [Related]
49. Impact of the Temporal Relationship Between Atrial Fibrillation and Heart Failure on Prognosis After Ablation. Tsuji A; Masuda M; Asai M; Iida O; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Okuno S; Hata Y; Mano T Circ J; 2020 Aug; 84(9):1467-1474. PubMed ID: 32684540 [TBL] [Abstract][Full Text] [Related]
50. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Cherian TS; Shrader P; Fonarow GC; Allen LA; Piccini JP; Peterson ED; Thomas L; Kowey PR; Gersh BJ; Mahaffey KW Am J Cardiol; 2017 Jun; 119(11):1763-1769. PubMed ID: 28416199 [TBL] [Abstract][Full Text] [Related]
51. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV; Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174 [TBL] [Abstract][Full Text] [Related]
52. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis. Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264 [TBL] [Abstract][Full Text] [Related]
53. Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction. Mercer BN; Koshy A; Drozd M; Walker AMN; Patel PA; Kearney L; Gierula J; Paton MF; Lowry JE; Kearney MT; Cubbon RM; Witte KK J Am Heart Assoc; 2018 Oct; 7(20):e009770. PubMed ID: 30371286 [TBL] [Abstract][Full Text] [Related]
54. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. Eberly LA; Day SM; Ashley EA; Jacoby DL; Jefferies JL; Colan SD; Rossano JW; Semsarian C; Pereira AC; Olivotto I; Ingles J; Seidman CE; Channaoui N; Cirino AL; Han L; Ho CY; Lakdawala NK JAMA Cardiol; 2020 Jan; 5(1):83-91. PubMed ID: 31799990 [TBL] [Abstract][Full Text] [Related]
55. Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. Reimer Jensen AM; Zierath R; Claggett B; Skali H; Solomon SD; Matsushita K; Konety S; Butler K; Kitzman DW; Biering-Sørensen T; Shah AM JAMA Cardiol; 2021 May; 6(5):509-520. PubMed ID: 33729428 [TBL] [Abstract][Full Text] [Related]
56. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Arvanitis M; Chan GG; Jacobson DR; Berk JL; Connors LH; Ruberg FL Amyloid; 2017 Dec; 24(4):253-255. PubMed ID: 29052438 [No Abstract] [Full Text] [Related]
57. Community-based care for the specialized management of heart failure: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(17):1-42. PubMed ID: 23074521 [TBL] [Abstract][Full Text] [Related]
59. Cardiovascular Disease Events and Mortality After Myocardial Infarction Among Black and White Adults: REGARDS Study. Blackston JW; Safford MM; Mefford MT; Freeze E; Howard G; Howard VJ; Naftel DC; Brown TM; Levitan EB Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e006683. PubMed ID: 33302710 [TBL] [Abstract][Full Text] [Related]
60. Transthyretin Cardiac Amyloidosis in Black Americans. Shah KB; Mankad AK; Castano A; Akinboboye OO; Duncan PB; Fergus IV; Maurer MS Circ Heart Fail; 2016 Jun; 9(6):e002558. PubMed ID: 27188913 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]